Abstract
It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors.
Keywords: CKD, angiotensin II, aldosterone, ARB, hypertension
Current Cardiology Reviews
Title: Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Volume: 4 Issue: 3
Author(s): Yasunobu Hirata, Arihiro Kiyosue, Masao Takahashi, Hiroshi Satonaka, Daisuke Nagata, Masataka Sata, Etsu Suzuki and Ryozo Nagai
Affiliation:
Keywords: CKD, angiotensin II, aldosterone, ARB, hypertension
Abstract: It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors.
Export Options
About this article
Cite this article as:
Hirata Yasunobu, Kiyosue Arihiro, Takahashi Masao, Satonaka Hiroshi, Nagata Daisuke, Sata Masataka, Suzuki Etsu and Nagai Ryozo, Progression of Renal Dysfunction in Patients with Cardiovascular Disease, Current Cardiology Reviews 2008; 4(3) . https://dx.doi.org/10.2174/157340308785160543
DOI https://dx.doi.org/10.2174/157340308785160543 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Current Pharmaceutical Design Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology How to Assess Sympathetic Nervous System Activity in Clinical Practice
Current Clinical Pharmacology Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Analgesic Herbal Medicines in the Treatment of Knee Osteoarthritis: A Systematic Review
Current Rheumatology Reviews General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) Mechanisms of Brain Signaling During Sepsis
Current Neuropharmacology Prevention of Ischemic Stroke: Surgery
Current Drug Targets Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention
Current Drug Targets Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science